共 349 条
[1]
Benvenuti S(2007)Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti–epidermal growth factor receptor antibody therapies Cancer Res 67 2643-2648
[2]
Sartore-Bianchi A(2012)Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials Eur J Cancer 48 1466-1475
[3]
Di Nicolantonio F(2008)Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients Br J Cancer 99 83-89
[4]
Zanon C(2008)Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 5705-5712
[5]
Moroni M(2013)Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 1023-1034
[6]
Veronese S(2008)Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone Clin Colorectal Cancer 7 184-190
[7]
Siena S(2014)PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17 Clin Cancer Res 20 744-753
[8]
Bardelli A(2010)Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal Trials 11 85-5930
[9]
Bokemeyer C(2009)Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 5924-1156
[10]
Cutsem EV(2013)Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication J Natl Cancer Inst 105 1151-721